Despite a slowing of tumor growth over the first 7 days of treatment, AZD8186 monotherapy did not positively impact overall survival, nor did it prolong response in either the BRAF PTEN or BRAF P53 models (Fig. 5B; Supplementary Fig. S9E, S9H, and S9I). This evidence concerns the gene BRAF and neoplasm.